Proteus Pharma
Proteus Pharma, a leading name in the pharmaceutical industry, is headquartered in Spain (ES) and operates extensively across Europe and beyond. Founded in 2005, the company has established itself as a key player in the development of innovative therapeutic solutions, particularly in the fields of oncology and rare diseases. With a strong focus on research and development, Proteus Pharma offers a range of unique products and services that address unmet medical needs. Their commitment to quality and efficacy has positioned them as a trusted partner in the healthcare sector. Notable achievements include successful collaborations with major healthcare institutions and a growing portfolio of patented therapies that reflect their dedication to advancing patient care.
DitchCarbon Score
How does Proteus Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Proteus Pharma's score of 21 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Proteus Pharma's reported carbon emissions
In 2022, Proteus Pharma reported carbon emissions of approximately 306,000,000 kg CO2e from Scope 1, 88,000,000 kg CO2e from Scope 2 (market-based), and 8,624,000,000 kg CO2e from Scope 3 emissions in Great Britain. This reflects a continued focus on understanding and managing their carbon footprint across various scopes. In 2021, the company recorded emissions of about 300,000,000 kg CO2e for Scope 1, 131,000,000 kg CO2e for Scope 2 (market-based), and 9,949,000,000 kg CO2e for Scope 3. The 2020 figures showed a significant Scope 3 emission total of approximately 14,260,000,000 kg CO2e, alongside 227,000,000 kg CO2e from Scope 2. Despite these substantial emissions, there are currently no specific reduction targets or initiatives disclosed by Proteus Pharma. The absence of documented reduction strategies suggests a need for further commitment to climate action within the industry context. As the company continues to assess its emissions, it may consider setting science-based targets to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Scope 1 | - | - | - |
| Scope 2 | 518,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | 00,000,000,000 | 00,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Proteus Pharma is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
